Nasdaq6d
J&J Seeks FDA Nod for Non-Muscle Invasive Bladder Cancer Drug
Johnson & Johnson JNJ has initiated a rolling submission with the FDA seeking approval for TAR-200, its investigational drug-device combination to treat certain patients with non-muscle invasive ...
Nasdaq6d
ImmunityBio Provides Update On FDA Submissions For 2025
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Nasdaq5d
INNOVATE Corp. Announces FDA Approval of MediBeacon® Transdermal GFR System for Kidney Function Assessment
The FDA has approved MediBeacon®'s TGFR system for noninvasive kidney function assessment, targeting both normal and impaired renal patients. INNOVATE Corp. announced the FDA approval of the ...
Nasdaq6d
FDA Approves LUMAKRAS With Vectibix For KRAS G12C-Mutated MCRC
(RTTNews) - Amgen, Inc. (AMGN) a biopharmaceutical company on Friday, announced that the FDA has approved LUMAKRAS or sotorasib in combination with Vectibix or panitumumab for the treatment of ...
Nasdaq6d
FDA Okays LLY's Omvoh for Second Inflammatory Bowel Disease Condition
Eli Lilly and Company LLY announced that the FDA has granted approval to its drug ... list of today’s Zacks #1 Rank (Strong Buy) stocks here. It's only 1/9,000th the size of NVIDIA which ...
Nasdaq5d
FDA Approves AstraZeneca's Calquence For Patients With Untreated Mantle Cell Lymphoma
(RTTNews) - AstraZeneca (AZN), on Friday, announced that the FDA has approved CALQUENCE in ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...
Nasdaq5d
FDA Okays AstraZeneca And Daiichi's Datroway For Metastatic HR-Positive, HER2-Negative Breast Cancer
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Nasdaq5d
Amgen's Lumakras+Vectibix Combo Gets FDA Approval For Metastatic Colorectal Cancer Treatment
Currently, Amgen's stock is trading at $272.83, up 1.26 percent on the Nasdaq. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those ...
Nasdaq5d
Pharma Stock Roundup: J&J's ITCI Buyout, LLY's Weak Q4 Sales
FDA’s Priority Tag to AZN/Daiichi’s Dato ... Here’s how the eight major stocks performed in the previous five trading sessions. Image Source: Zacks Investment Research In the last five ...
Atara extends losses after FDA clinical hold
Atara Biotherapeutics (ATRA) stock slips as company faces an FDA clinical hold after rejection of lead candidate Ebvallo.
Nasdaq6d
Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?
The FDA approved Alyftrek nearly two weeks before ... analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one ...
Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia
Only dual route gene transfer therapy in development to treat Friedreich’s ataxia with FDA IND clearance and Fast Track designation ...